You are here

Articles

CML Horizons Conference Report: Lisbon Portugal May 17th - 19th 2019

published: 28 May 2019

Early results of lower dose dasatinib (50 mg daily) as frontline therapy

published: 22 May 2019

TKI Discontinuation Criteria Established in Updated NCCN Guidelines

published: 27 March 2019

Skeletal muscle toxicity associated with TKIs in CML patients

published: 18 March 2019

Falsified Iclusig / ponatinib traded globally

published: 31 January 2019

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after TFR attempts

published: 5 December 2018

UCLH study: web-based video consultations

published: 11 November 2018

£3M Award for Pioneering Scottish Trial for Leukaemia (CML)

published: 27 September 2018

BCR-ABL1 levels increase in peripheral blood but not in granulocytes after physical exercise

published: 21 August 2018

Pepsi or Coke? Influence of acid on dasatinib absorption

published: 21 August 2018

UK CML Patient Conference 2018 (22 Sept): Video Recordings Now Available

published: 14 August 2018

Chronic myeloid leukemia and pregnancy: patient and partner perspectives

published: 29 July 2018

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors

published: 9 July 2018

Early Results of Lower Dose Dasatinib (50 mg Daily) as Frontline Therapy

published: 5 May 2018

Help CML Support by registering with AmazonSmile

published: 1 March 2018

Dasatinib dose management for the treatment of chronic myeloid leukemia

published: 28 February 2018

Long-Term Outcome Of Nilotinib 400 Mg Twice Daily In First-Line Treatment

published: 27 February 2018

Considerations for Successful Treatment-free Remission

published: 22 February 2018

Pancreatic enzyme elevation in patients treated with nilotinib

published: 20 February 2018

Once a day nilotinib: A Real Life Observational Study

published: 22 December 2017